ALXO — ALX Oncology Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $80.33m
- $13.24m
- 25
- 33
- 74
- 39
Annual cashflow statement for ALX Oncology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -45.7 | -83.5 | -123 | -161 | -135 |
| Depreciation | |||||
| Non-Cash Items | 7 | 19.3 | 24.1 | 21.3 | 24.5 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.247 | -4.03 | 9.85 | 8.3 | -12.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -38.3 | -68.1 | -89.2 | -130 | -122 |
| Capital Expenditures | -0.031 | -4.92 | -1.43 | -1.27 | -0.447 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.641 | — | -234 | 45.9 | 86.7 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.61 | -4.92 | -235 | 44.7 | 86.3 |
| Financing Cash Flow Items | -10.4 | — | -0.655 | 58.9 | 29.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 463 | 2.47 | 9.86 | 59.3 | 30.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 425 | -70.6 | -315 | -26.4 | -4.84 |